388 related articles for article (PubMed ID: 29145865)
1. The endonuclease EEPD1 mediates synthetic lethality in RAD52-depleted BRCA1 mutant breast cancer cells.
Hromas R; Kim HS; Sidhu G; Williamson E; Jaiswal A; Totterdale TA; Nole J; Lee SH; Nickoloff JA; Kong KY
Breast Cancer Res; 2017 Nov; 19(1):122. PubMed ID: 29145865
[TBL] [Abstract][Full Text] [Related]
2. EEPD1 Rescues Stressed Replication Forks and Maintains Genome Stability by Promoting End Resection and Homologous Recombination Repair.
Wu Y; Lee SH; Williamson EA; Reinert BL; Cho JH; Xia F; Jaiswal AS; Srinivasan G; Patel B; Brantley A; Zhou D; Shao L; Pathak R; Hauer-Jensen M; Singh S; Kong K; Wu X; Kim HS; Beissbarth T; Gaedcke J; Burma S; Nickoloff JA; Hromas RA
PLoS Genet; 2015 Dec; 11(12):e1005675. PubMed ID: 26684013
[TBL] [Abstract][Full Text] [Related]
3. Endonuclease EEPD1 Is a Gatekeeper for Repair of Stressed Replication Forks.
Kim HS; Nickoloff JA; Wu Y; Williamson EA; Sidhu GS; Reinert BL; Jaiswal AS; Srinivasan G; Patel B; Kong K; Burma S; Lee SH; Hromas RA
J Biol Chem; 2017 Feb; 292(7):2795-2804. PubMed ID: 28049724
[TBL] [Abstract][Full Text] [Related]
4. The homologous recombination component EEPD1 is required for genome stability in response to developmental stress of vertebrate embryogenesis.
Chun C; Wu Y; Lee SH; Williamson EA; Reinert BL; Jaiswal AS; Nickoloff JA; Hromas RA
Cell Cycle; 2016; 15(7):957-62. PubMed ID: 26900729
[TBL] [Abstract][Full Text] [Related]
5. Distinct roles of RAD52 and POLQ in chromosomal break repair and replication stress response.
Kelso AA; Lopezcolorado FW; Bhargava R; Stark JM
PLoS Genet; 2019 Aug; 15(8):e1008319. PubMed ID: 31381562
[TBL] [Abstract][Full Text] [Related]
6. MiR223-3p promotes synthetic lethality in BRCA1-deficient cancers.
Srinivasan G; Williamson EA; Kong K; Jaiswal AS; Huang G; Kim HS; Schärer O; Zhao W; Burma S; Sung P; Hromas R
Proc Natl Acad Sci U S A; 2019 Aug; 116(35):17438-17443. PubMed ID: 31395736
[TBL] [Abstract][Full Text] [Related]
7. Pan-cancer analysis of co-occurring mutations in RAD52 and the BRCA1-BRCA2-PALB2 axis in human cancers.
Hamid AB; Frank LE; Bouley RA; Petreaca RC
PLoS One; 2022; 17(9):e0273736. PubMed ID: 36107942
[TBL] [Abstract][Full Text] [Related]
8. RAD52 inactivation is synthetically lethal with deficiencies in BRCA1 and PALB2 in addition to BRCA2 through RAD51-mediated homologous recombination.
Lok BH; Carley AC; Tchang B; Powell SN
Oncogene; 2013 Jul; 32(30):3552-8. PubMed ID: 22964643
[TBL] [Abstract][Full Text] [Related]
9. BRCA1 controls homologous recombination at Tus/Ter-stalled mammalian replication forks.
Willis NA; Chandramouly G; Huang B; Kwok A; Follonier C; Deng C; Scully R
Nature; 2014 Jun; 510(7506):556-9. PubMed ID: 24776801
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic exploitation of tumor cell defects in homologous recombination.
Powell SN; Kachnic LA
Anticancer Agents Med Chem; 2008 May; 8(4):448-60. PubMed ID: 18473729
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor Cells.
Sullivan-Reed K; Bolton-Gillespie E; Dasgupta Y; Langer S; Siciliano M; Nieborowska-Skorska M; Hanamshet K; Belyaeva EA; Bernhardy AJ; Lee J; Moore M; Zhao H; Valent P; Matlawska-Wasowska K; Müschen M; Bhatia S; Bhatia R; Johnson N; Wasik MA; Mazin AV; Skorski T
Cell Rep; 2018 Jun; 23(11):3127-3136. PubMed ID: 29898385
[TBL] [Abstract][Full Text] [Related]
12. Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile.
Cramer-Morales K; Nieborowska-Skorska M; Scheibner K; Padget M; Irvine DA; Sliwinski T; Haas K; Lee J; Geng H; Roy D; Slupianek A; Rassool FV; Wasik MA; Childers W; Copland M; Müschen M; Civin CI; Skorski T
Blood; 2013 Aug; 122(7):1293-304. PubMed ID: 23836560
[TBL] [Abstract][Full Text] [Related]
13. Selective killing of homologous recombination-deficient cancer cell lines by inhibitors of the RPA:RAD52 protein-protein interaction.
Al-Mugotir M; Lovelace JJ; George J; Bessho M; Pal D; Struble L; Kolar C; Rana S; Natarajan A; Bessho T; Borgstahl GEO
PLoS One; 2021; 16(3):e0248941. PubMed ID: 33784323
[TBL] [Abstract][Full Text] [Related]
14. Reappearance from Obscurity: Mammalian Rad52 in Homologous Recombination.
Hanamshet K; Mazina OM; Mazin AV
Genes (Basel); 2016 Sep; 7(9):. PubMed ID: 27649245
[TBL] [Abstract][Full Text] [Related]
15. The RAD52 S346X variant reduces risk of developing breast cancer in carriers of pathogenic germline BRCA2 mutations.
Adamson AW; Ding YC; Mendez-Dorantes C; Bailis AM; Stark JM; Neuhausen SL
Mol Oncol; 2020 Jun; 14(6):1124-1133. PubMed ID: 32175645
[TBL] [Abstract][Full Text] [Related]
16. RAD52 influences the effect of BRCA1/2 missense variants on homologous recombination and gene reversion in Saccharomyces cerevisiae.
Lodovichi S; Bellè F; Mercatanti A; Spugnesi L; Cozzani C; Caligo MA; Cervelli T; Galli A
FEMS Yeast Res; 2022 Jun; 22(1):. PubMed ID: 35472165
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous Targeting of DNA Polymerase Theta and PARP1 or RAD52 Triggers Dual Synthetic Lethality in Homologous Recombination-Deficient Leukemia Cells.
Sullivan-Reed K; Toma MM; Drzewiecka M; Nieborowska-Skorska M; Nejati R; Karami A; Wasik MA; Sliwinski T; Skorski T
Mol Cancer Res; 2023 Oct; 21(10):1017-1022. PubMed ID: 37358557
[TBL] [Abstract][Full Text] [Related]
18. EEPD1 promotes repair of oxidatively-stressed replication forks.
Jaiswal AS; Kim HS; Schärer OD; Sharma N; Williamson EA; Srinivasan G; Phillips L; Kong K; Arya S; Misra A; Dutta A; Gupta Y; Walter CA; Burma S; Narayan S; Sung P; Nickoloff JA; Hromas R
NAR Cancer; 2023 Mar; 5(1):zcac044. PubMed ID: 36683914
[TBL] [Abstract][Full Text] [Related]
19. RAD52 aptamer regulates DNA damage repair and STAT3 in BRCA1/BRCA2‑deficient human acute myeloid leukemia.
Xu Y; Lin Y; Luo Y; Yang Y; Long B; Fang Z; Liu L; Zhang J; Zhang X
Oncol Rep; 2020 Oct; 44(4):1455-1466. PubMed ID: 32945515
[TBL] [Abstract][Full Text] [Related]
20. Molecular pathways: understanding the role of Rad52 in homologous recombination for therapeutic advancement.
Lok BH; Powell SN
Clin Cancer Res; 2012 Dec; 18(23):6400-6. PubMed ID: 23071261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
